- Paradisi F, Corti G, Mangani V. Urosepsis in the critical care unit. Crit Care Clin 1998; 1:165–180.
- Bjerklund Johansen TE, Cek M, Naber K, et al. Prevalence of hospital-acquired urinary tract infections
in urology departments. Eur Urol 2007; 51:1100–1111. - Cunha BA. Sepsis and septic shock: selection of empiric antibiotic therapy. Crit Care Clin 2008;
24:313–324. - Cunha BA. Antibiotic Essentials. 8th ed. Sudbury, MA: Jones & Bartlett; 2009.
- Cunha BA. Antimicrobial therapy of multi-drug resistantS. pneumoniaeVRE & MRSA. Med Clin
North Am 2006; 90:1165–1182. - Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;
329:1328–1334. - Carson C, Naber KG. Role of fluoroquinolones in the treatment of serious bacterial urinary tract
infections. Drugs 2004; 64:1359–1373. - Hendrickson JR. A cost-effective strategy for managing complicated urinary tract infections. J Crit Ill
1996; 11(suppl):S49. - Henske-Bar-Meir R, Yinnon AM, Rudensky B, et al. Assessment of the clinical significance of
production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae. Infection 2006;
34:66–74. - Koomanachai P, Tiengrim S, Kiratisin P, et al. Efficacy and safety of colistin (colistimethate sodium)
for therapy of infections caused by multidrug-resistantPseudomonas aeruginosaandAcinetobacter
baumanniiin Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11:402–406. - Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B againstPseudomonas
aeruginosa. Antimicrob Agents Chemother 2005; 49:3624–3630. - Zavaski AP, Goldani LZ, Li J, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a
critical review. J Antimicrob Chemother 2007; 60:1206–1215. - Mastoraki A, Douka E, Kriaras I, et al.Pseudomonas aeruginosasusceptible only to colistin in intensive
care unit patients. Surg Infect (Larchmt) 2008; 9:153–160. - Cunha BA. Once daily tigecycline therapy of multidrug-resistant and non-multidrug resistant gram-
negative bacteremias. J Chemother 2007; 19:232–233. - Cunha BA, McDermott B, Nausheen S. A single once daily high dose therapy of tigecycline of a multi-
drug resistant (MDR)Klebsiella pneumoniaeandEnterobacter agglomeransnosocomial urinary tract
infection. J Chemother 2008; 19:753–754. - Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR)
Klebsiella pneumoniaeor MDRAcinetobacter baumanniiuroscpsis. J Clin Microbiol 2009; 47:1613. - Holloway KP, Rouphael NG, Wells JB, et al. Polymyxin B and doxycycline use in patients with
multidrug-resistantAcinetobacter baumanniiinfections in the intensive care unit. Ann Pharmacother
2006; 40:1939–1945. - Mezzatesta ML, Trovato G, Gona F, et al. In vitro activity of tigecycline and comparators against
carbapenem-susceptible and resistantAcinetobacter baumanniiclinical isolates in Italy. Ann Clin
Microbiol Antimicrob 2008; 7:4. - Krueger WA, Kempf VA, Peiffer M, et al. Treatment with tigecycline of recurrent urosepsis caused by
extended-spectrum-beta-lactamase-producingEscherichia coli. J Clin Microbiol 2008; 46:817–820. - Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J Clin
Microbiol 2008; 46:1892–1893. - Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections
due to multidrug-resistantAcinetobacter baumannii. Clin Infect Dis 2003; 36:1268–1274.
294 Cunha